These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16700870)

  • 1. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
    Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE
    J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
    Kaaja R; Manhem K; Tuomilehto J
    Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of moxonidine in elderly patients with resistant hypertension.
    Martin U; Hill C; O' Mahony D
    J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
    Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P
    Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Haenni A; Lithell H
    J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
    Velliquette RA; Ernsberger P
    J Pharmacol Exp Ther; 2003 Aug; 306(2):646-57. PubMed ID: 12756274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
    Masajtis-Zagajewska A; Majer J; Nowicki M
    Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension.
    Koh KK; Han SH; Ahn JY; Chung WJ; Lee Y; Shin EK
    Int J Cardiol; 2009 Mar; 133(1):23-31. PubMed ID: 18199500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrasting metabolic effects of antihypertensive agents.
    Velliquette RA; Ernsberger P
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1104-11. PubMed ID: 14557373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.